These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 19372867)

  • 21. Structured treatment interruptions for the management of HIV infection.
    Lori F; Lisziewicz J
    JAMA; 2001 Dec; 286(23):2981-7. PubMed ID: 11743839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study.
    Ananworanich J; Siangphoe U; Hill A; Cardiello P; Apateerapong W; Hirschel B; Mahanontharit A; Ubolyam S; Cooper D; Phanuphak P; Ruxrungtham K
    J Acquir Immune Defic Syndr; 2005 Aug; 39(5):523-9. PubMed ID: 16044002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structured treatment interruption in patients infected with HIV: a new approach to therapy.
    Gulick RM
    Drugs; 2002; 62(2):245-53. PubMed ID: 11817971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Earlier initiation of antiretroviral therapy in treatment-naïve patients: implications of results of treatment interruption trials.
    Neaton JD; Grund B
    Curr Opin HIV AIDS; 2008 Mar; 3(2):112-7. PubMed ID: 19372951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial.
    Butler K; Inshaw J; Ford D; Bernays S; Scott K; Kenny J; Klein N; Turkova A; Harper L; Nastouli E; Paparini S; Choudhury R; Rhodes T; Babiker A; Gibb D
    Health Technol Assess; 2016 Jun; 20(49):1-108. PubMed ID: 27377073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interruptions of antiretroviral therapy in children and adolescents with HIV infection in clinical practice: a retrospective cohort study in the USA.
    Rakhmanina N; Lam KS; Hern J; Young HA; Walters A; Castel AD
    J Int AIDS Soc; 2016; 19(1):20936. PubMed ID: 27797320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
    Nuesch R; Ananworanich J; Sirivichayakul S; Ubolyam S; Siangphoe U; Hill A; Cooper D; Lange J; Phanuphak P; Ruxrungtham K
    Clin Infect Dis; 2005 Mar; 40(5):728-34. PubMed ID: 15714420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcomes after an unstructured treatment interruption in children and adolescents with perinatally acquired HIV infection.
    Saitoh A; Foca M; Viani RM; Heffernan-Vacca S; Vaida F; Lujan-Zilbermann J; Emmanuel PJ; Deville JG; Spector SA
    Pediatrics; 2008 Mar; 121(3):e513-21. PubMed ID: 18310171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD4+ cell-count-guided treatment interruptions in chronic HIV-infected patients with good response to highly active antiretroviral therapy.
    Boschi A; Tinelli C; Ortolani P; Moscatelli G; Morigi G; Arlotti M
    AIDS; 2004 Dec; 18(18):2381-9. PubMed ID: 15622314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment interruption strategies: how great are the risks?
    Paton NI
    Curr Opin Infect Dis; 2008 Feb; 21(1):25-30. PubMed ID: 18192782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial.
    Ananworanich J; Gayet-Ageron A; Le Braz M; Prasithsirikul W; Chetchotisakd P; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawasdikul S; Sirivichayakul S; Cavassini M; Karrer U; Genné D; Nüesch R; Vernazza P; Bernasconi E; Leduc D; Satchell C; Yerly S; Perrin L; Hill A; Perneger T; Phanuphak P; Furrer H; Cooper D; Ruxrungtham K; Hirschel B; ;
    Lancet; 2006 Aug; 368(9534):459-65. PubMed ID: 16890832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration.
    Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration
    Lancet HIV; 2019 Feb; 6(2):e105-e115. PubMed ID: 30723008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.
    León A; Martinez E; Milinkovic A; Mora B; Mallolas J; Blanco JL; Larrousse M; Laguno M; Gallart T; Plana M; Gatell JM; Garcia F
    J Antimicrob Chemother; 2009 Jan; 63(1):184-8. PubMed ID: 19001447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Virological rebound and its consequences during treatment interruption.
    van Lunzen J; Hoffmann C
    Curr Opin HIV AIDS; 2007 Jan; 2(1):1-5. PubMed ID: 19372858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102.
    Henry K; Katzenstein D; Cherng DW; Valdez H; Powderly W; Vargas MB; Jahed NC; Jacobson JM; Myers LS; Schmitz JL; Winters M; Tebas P;
    J Acquir Immune Defic Syndr; 2006 Jun; 42(2):140-8. PubMed ID: 16760795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.
    Ruiz L; Paredes R; Gómez G; Romeu J; Domingo P; Pérez-Alvarez N; Tambussi G; Llibre JM; Martínez-Picado J; Vidal F; Fumaz CR; Clotet B;
    AIDS; 2007 Jan; 21(2):169-78. PubMed ID: 17197807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune modulators and treatment interruption.
    García F; Fumero E; Gatell JM
    Curr Opin HIV AIDS; 2008 Mar; 3(2):124-30. PubMed ID: 19372953
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.